Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer

Table 4 Unadjusted and V₂₀ adjusted Cox proportional-hazards analyses of clinical factors of type II ILD

	Unadjusted			V₂₀ adjusted
	HR	95%CI	p value	HR	95%CI	p value
Age (years)	1.012	0.96–1.07	0.672	1.004	0.95–1.06	0.894
Sex	0.371	0.08–1.70	0.201	0.404	0.09–1.85	0.243
Brinkman index	1.000	1.000-1.001	0.297	1.000	1.000-1.001	0.437
Pulmonary fibrosis score	0.512	0.07–4.05	0.525	1.024	0.12–8.94	0.983
Pulmonary emphysema score	1.014	0.61–1.69	0.957	1.038	0.63–1.72	0.885
LDH (U/L)	1.010	1.005–1.015	< 0.001	1.009	1.004–1.014	< 0.001
CRP (mg/dL)	1.146	0.98–1.34	0.091	1.133	0.97–1.33	0.126
HbA1c (%)	1.896	1.38–2.60	< 0.001	1.842	1.35–2.51	< 0.001
Glucose (mg/dL)	1.017	1.004–1.031	0.011	1.017	1.003–1.031	0.018
KL-6 (U/mL)	1.000	0.998–1.002	0.962	1.001	0.998–1.003	0.666
Clinical stage of lung cancer	1.104	0.71–1.71	0.659	1.131	0.74–1.73	0.571
Chemotherapy	1.185	0.32–4.38	0.799	1.377	0.37–5.16	0.635
Durvalumab	0.690	0.22–2.18	0.527	0.576	0.18–1.85	0.354
V₂₀(%)l1195	1.070	0.998–1.148	0.058
V ₅ (%)	1.021	0.98–1.06	0.323
MLD (Gy)	1.120	0.97–1.29	0.120
Vs5 (cc)	1.000	0.999–1.001	0.745	1.001	1.000-1.002	0.082
Lung volume (cc)	1.000	0.999–1.001	0.855	1.000	1.000-1.001	0.292

ISSN: 1748-717X